Oramed Pharmaceuticals (ORMP) Cash & Current Investments (2010 - 2026)

Oramed Pharmaceuticals has reported Cash & Current Investments for 17 years, with the latest figure at $18.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 81.88% year-over-year to $18.2 million; the trailing twelve-month figure through Mar 2026 stood at $18.2 million (down 81.88% YoY), and the FY2025 full-year result was $51.4 million, down 53.18% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $18.2 million, down from $51.4 million in the prior quarter.
• The five-year high for Cash & Current Investments was $154.3 million in Q3 2022, with the low at $7.7 million in Q2 2023.
• Historically, Cash & Current Investments has averaged $83.6 million across 5 years, with a median of $98.9 million in 2024.
• Annual changes were most pronounced in 2023 — Cash & Current Investments sank 93.94% — and 2024, when it jumped 1022.32%.
• Oramed Pharmaceuticals' Cash & Current Investments stood at $44.2 million in 2022, then soared by 136.01% to $104.3 million in 2023, then gained by 5.14% to $109.7 million in 2024, then sank by 53.18% to $51.4 million in 2025, then tumbled by 64.63% to $18.2 million in 2026.
• The last three Cash & Current Investments figures came in at $18.2 million (Q1 2026), $51.4 million (Q4 2025), and $125.7 million (Q3 2025), per Business Quant data.